|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
New insights into progesterone actions on prolactin secretion and prolactinoma development.
|
31521709 |
2019 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Prolactinomas with lack of size regression and failure to reach normalization of PRL levels by 12 months may be considered for other management strategies.
|
31181361 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The discovery of dopamine inhibitory effects on prolactin secretion has led to an era of successful dopaminergic therapy for prolactinomas.
|
30852578 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prolactin-Secreting Lung Adenocarcinoma Metastatic to the Pituitary Mimicking a Prolactinoma: A Case Report.
|
30137505 |
2019 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Conclusions Cabergoline effectively lowers prolactin levels and may reduce tumour mass in paediatric and adolescent patients with prolactinomas.
|
31323004 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prolactin-secreting adenomas (prolactinomas) are the most common secreting adenomas of the pituitary.
|
30404098 |
2019 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Prolactinomas are usually benign and controllable tumors as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and tumor volume.
|
30677777 |
2019 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, inhibition or overexpression of miR-1299 in primary tumor cells confirmed that drug-resistant prolactinoma promoted prolactin secretion by promoting miR-1299 expression and reducing intracellular FOXO1.
|
31582213 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We enrolled 149 patients (108 F/41 M) with PRLs (110 micro/39 macro) and 143 subjects (100 F/43 M) with NFPA (n = 96, 56 micro/40 macro) or ES (n = 47), with normal serum prolactin.
|
30406929 |
2019 |
|
Prolactinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Examples include: association of prolactinomas with paternal deprivation and with stressful life events; pseudocyesis; acute life event-driven episodes of galactorrhea; episodes of rapid weight gain following a life event; prolactin surges (without associated cortisol surges) following some psychological stresses.
|
31062250 |
2019 |
|
Prolactinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A significant negative relationship between prolactin levels and MCS (r = -0.30, P < 0.01) and PCS (r = -0.41, P < 0.01) were found in prolactinomas.
|
30548674 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
PRL values >250 ng/mL are highly suggestive of prolactinomas and virtually exclude nonfunctioning pituitary adenomas (NFPAs) and other sellar masses as the etiology of hyperprolactinemia.
|
30889571 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
mPRs represent a novel target for PRL inhibition in experimental prolactinomas.
|
30856609 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pituitary adenomas (PAs) are one of the most common intracranial tumors; approximately half of PAs are prolactin (PRL)-secreting PAs (prolactinomas).
|
31692290 |
2019 |
|
Prolactinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
At diagnosis, heterogeneous prolactinomas were more frequent in men (68% vs. 28.9%, p ≤ 0.011), larger (median area 304.5 mm<sup>2</sup> vs. 56.5 mm<sup>2</sup>, p ≤ 0.021), taller (mean height 18.6 mm vs. 9.9 mm, p < 0.001), more secreting (median PRL ULN_area 23 µg/L/cm<sup>2</sup> vs. 12.6 µg/L/cm<sup>2</sup>, p ≤ 0.032) and had poorer hormonal response to DA as compared with homogeneous prolactinomas.
|
30267354 |
2019 |
|
Hyperprolactinemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The study enrolled 30 young women with mild hyperprolactinemia (serum prolactin levels in the range between 25 and 50ng/mL), 15 of whom were later treated with bromocriptine (5-10mg daily), as well as 14 age- and weight-matched healthy women.
|
29475005 |
2018 |
|
Hyperprolactinemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Prolactin takes calcium from the skeletal system following increased Prlr gene expression in the vertebrae to maintain calcium homeostasis, which increases the harmful effect on bone metabolism compared to that of physiological hyperprolactinaemia.
|
30143940 |
2018 |
|
Hyperprolactinemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Abnormalities in thyroid function and hyperprolactinemia are well-known causes of infertility, but whether thyrotropin (TSH) and prolactin levels within the normal range are associated with UI is unknown.
|
29272395 |
2018 |
|
Hyperprolactinemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although there were significant differences in the prevalence of hyperprolactinemia and metabolic syndrome according to the antipsychotic received, multivariant regression analysis did not show a correlation between sexual dysfunction and prolactin, sexual hormones, type of antipsychotic received, psychotic psychopathology or metabolic syndrome.
|
30552811 |
2018 |
|
Hyperprolactinemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Future prospects for hyperprolactinemia may require diagnostic criteria using free prolactin levels and so MPRL fraction measurement is important for the diagnosis and treatment of patients with obstetric and gynecological symptoms.
|
29162783 |
2018 |
|
Hyperprolactinemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
It was also demonstrated that prolactin played an important role in body weight regulation and hyperprolactinemia can promote appetite and accelerate fat deposition.
|
30124145 |
2018 |
|
Hyperprolactinemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Non-gPRLoma was considered when tumor diameter was ≥ 10 mm and<40 mm associated to hyperprolactinemia (PRL≥200 ng/ml).
|
30396208 |
2018 |
|
Hyperprolactinemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The odds of hyperprolactinemia in the no/low prolactin elevation cohort were 4-5-times lower than that in the high/moderate prolactin elevation cohort (odds ratio =0.21; p < .001).
|
30188234 |
2018 |
|
Hyperprolactinemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In summary, a reduction in prolactin levels by cabergoline in patients with hyperprolactinaemia is followed by an improvement in cognitive abilities.
|
29035904 |
2018 |
|
Hyperprolactinemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Responsiveness to dopamine agonists; deterioration of hyperprolactinemia may be diagnostic for prolactin-producing uterine leiomyomas, although further research is required.
|
28925774 |
2018 |